Trial reportAnnals of surgical oncology2023
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial.
Trial report in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01801176 (Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Local aggressiveness and prognostic prediction in desmoid-type fibromatosis: insights fromAnnals of nuclear medicine · 2026Article
- Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis Using Radiomics: An International Multi-center Cohort Study.Annals of surgical oncology · 2026Article
- Percutaneous Management of Desmoid Tumors.Current oncology reports · 2026Review
- Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.European radiology experimental · 2026Article
- Intra-abdominal aggressive fibromatosis: a single-center case series of 12 patients focusing on surgical management and clinicopathological features.BMC gastroenterology · 2026Article
- Management of Desmoid Tumors.Current oncology reports · 2025Review
- Surgical Management of Desmoid Tumors-Patient Selection, Timing, and Approach.Current oncology (Toronto, Ont.) · 2025Review
- Cryotherapy in the Treatment of Extra-Abdominal Desmoid Tumors-A Review.Current oncology (Toronto, Ont.) · 2025Review
- Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Observational
- Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.Frontiers in oncology · 2025Article
- Mesenchymal Tumor Management: Integrating Surgical and Non-Surgical Strategies in Different Clinical Scenarios.Cancers · 2024Review
- Letter to the Editor on "Volume-based 18F-FDG-PET/CT predicts prognosis and outcome of active surveillance for intra-abdominal desmoid tumor".Abdominal radiology (New York) · 2024Article
- Desmoid tumour in an inguinal hernia in a patient with a previous diagnosis of melanoma.Ecancermedicalscience · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStabilization or spontaneous regressions are demonstrated in more than half of patients affected by primary desmoid-type fibromatosis (DF) in retrospective studies. The objective of this phase II study was to prospectively assess the behavior of primary sporadic DT managed by active surveillance (AS).
methodsThis prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall. At inclusion, all patients were initially placed on AS. Follow-up was based on clinical and radiological evaluation by magnetic resonance imaging (MRI) performed at 1, 3, 6, 9, and 12 months, and then every 6 months for 3 years. The primary endpoint was progression-free survival (PFS) at 3 years according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as evaluated by a Central Review Board.
resultsBetween 2012 and 2015, 100 patients were enrolled. The female/male ratio was 8 and the median age was 34 years (interquartile range [IQR] 30.8-43.9). Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%). At progression (48 patients), 23 patients received active treatment. Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs). The median time to PR was 31.7 months (25.3-not available).
conclusionsThese data support the use of AS as the primary approach to select patients with peripheral DF who require aggressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.